R126
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 122
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- OXIDATIVE_PHOSPHORYLATION+0.390
- ANGIOGENESIS+0.340
- INTERFERON_ALPHA_RESPONSE+0.240
- ADIPOGENESIS+0.230
- FATTY_ACID_METABOLISM+0.230
- ANDROGEN_RESPONSE+0.180
- PEROXISOME+0.170
- COMPLEMENT+0.160
- UV_RESPONSE_DN+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.340
- E2F_TARGETS-0.320
- APICAL_SURFACE-0.290
- G2M_CHECKPOINT-0.290
- KRAS_SIGNALING_DN-0.240
- APICAL_JUNCTION-0.230
- WNT_BETA_CATENIN_SIGNALING-0.210
- HYPOXIA-0.200
- MYOGENESIS-0.170
- HEDGEHOG_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899988 | — | — | 0.736 |
| 2 | BS_N210XMKR | low-grade glioma | — | 0.712 |
| 3 | e59f49c0-d7ce-44c3-9590-9b65128d7f8b | — | — | 0.693 |
| 4 | R388 | — | — | 0.690 |
| 5 | TCGA-5N-A9KM-01A-11R-A42T-07 | — | — | 0.682 |
| 6 | C3N-02088 | — | cohortA1 | 0.671 |
| 7 | SJEPD030146_D1.RNA-Seq | EPN | Supratentorial EPN | 0.670 |
| 8 | MBCProject_5799_T1_RNA | — | B | 0.667 |
| 9 | 10013d81-e167-4aa0-b548-5bb359ed403a | — | — | 0.665 |
| 10 | SRR4195645 | — | — | 0.665 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |